Key Takeaways
- CNC shares plummeted 14% on Tuesday, ranking as the S&P 500’s biggest loser for the session
- ACA marketplace membership projected to decline to 3.5 million by Q1’s conclusion, down sharply from December’s 5.5 million
- Management confirmed adjusted EPS forecast exceeding $3 for fiscal 2026
- Mizuho analysts reduced their price objective from $47 down to $41 while keeping a Neutral stance
- Medicare Advantage segment continues operating in negative margin territory with expectations for this to persist into 2026
Investors holding Centene shares have endured a turbulent year, and Tuesday’s session delivered another painful blow. The healthcare coverage provider saw its stock crater 14% following CEO Sarah London’s presentation at the Barclays Global Healthcare Conference, where her remarks about membership losses triggered a sharp selloff.
During her address to conference participants, London confirmed that Centene’s three primary business segments remain positioned to meet 2026 objectives. The executive reiterated the company’s adjusted earnings forecast of more than $3 per share — aligning precisely with the $3 consensus projection from FactSet-tracked Wall Street analysts.
However, the market response was decidedly negative. With guidance failing to deliver any positive surprises, market participants focused their attention squarely on the troubling enrollment trends.
The healthcare insurer now projects finishing the first quarter with approximately 3.5 million members in its ACA marketplace portfolio, representing a substantial decrease from December’s 5.5 million figure. As of February reporting, the company maintained 3.6 million enrolled individuals.
London indicated management had forecasted industry-wide contraction “somewhere between the high teens and the mid-thirties” on a percentage basis. The CEO noted Centene expected its performance would fall “at the higher end of that and possibly higher than the top end of that.”
She explained that strategic pricing adjustments implemented at year-start contributed to the membership exodus, as the organization chose to emphasize profitability enhancement over subscriber acquisition.
Medicare Advantage Segment Remains Unprofitable
The company’s Medicare Advantage operations continue dragging down overall performance metrics. This division operated at negative margins throughout 2025 and management anticipates slightly sub-zero profitability extending through 2026, with break-even status targeted for 2027.
Adding to investor anxiety is the pending final rate announcement from the Centers for Medicare and Medicaid Services, scheduled for release no later than April 6. The Trump administration’s earlier proposal to maintain essentially flat Medicare reimbursement rates for 2027 previously hammered Centene and competing health insurers.
London confirmed the organization submitted formal feedback to CMS regarding the Advance Rate Notice and voiced optimism that finalized rates would more appropriately account for current medical expenditure patterns affecting the entire sector.
Wall Street’s Response
Mizuho analysts acted swiftly following the conference presentation. The investment firm lowered its Centene price objective to $41 from the previous $47 level while maintaining its Neutral investment rating.
Mizuho pointed to concerns surrounding health insurance exchange member attrition and specialty pharmaceutical cost trajectories. The firm indicated it’s implementing a more cautious valuation approach pending improved visibility into the ultimate severity of enrollment challenges.
Truist Securities adopted a contrarian stance, preserving its Buy recommendation with a $49 price objective, emphasizing margin expansion potential and leadership team conviction. Cantor Fitzgerald maintained a Neutral position with a $41 target, characterizing 2026’s operating landscape as demanding.
For perspective, Centene has declined 9.7% during 2026, compared with a modest 0.7% retreat for the broader S&P 500 index.
The stock has nonetheless outperformed certain industry competitors. Molina Healthcare has fallen 17% year-to-date, Elevance Health is down 18%, and UnitedHealth Group has surrendered 14%.
Centene’s fourth quarter 2025 financial results revealed an adjusted diluted loss of $1.19 per share, marginally surpassing expectations for a $1.22 loss. Top-line revenue reached $49.73 billion, exceeding the $48.39 billion analyst estimate.
InvestingPro calculates Centene’s intrinsic value at $62.11, with Wall Street forecasting full-year 2026 EPS of $3.05.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
